Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Kidney cancer

Neoadjuvant targeted therapies in renal cell carcinoma

Nature Reviews Urology volume 7, pages 63–64 (2010)Cite this article

Subjects

Neoadjuvant targeted therapy can be used in patients with unresectable locally advanced, locally recurrent or metastatic renal cell carcinoma to induce cytoreduction before surgical resection. The efficacy of this multimodal therapy is still unproven, however, and must be balanced against a potential higher risk of perioperative complications.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Thomas, A. A. et al. Surgical resection of renal cell carcinoma after targeted therapy. J. Urol. 182, 881–886 (2009).

    Article  Google Scholar 

  2. Flanigan, R. C. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071–1076 (2004).

    Article  Google Scholar 

  3. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).

    Article  CAS  Google Scholar 

  4. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).

    Article  CAS  Google Scholar 

  5. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).

    Article  CAS  Google Scholar 

  6. Amin, C. et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72, 864–868 (2008).

    Article  Google Scholar 

  7. Bex, A. et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J. Urol. 27, 533–539 (2009).

    Article  CAS  Google Scholar 

  8. Karakiewicz, P. I. et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur. Urol. 53, 845–848 (2008).

    Article  Google Scholar 

  9. Shuch, B. et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 102, 692–696 (2008).

    Article  Google Scholar 

  10. Margulis, V. et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 180, 94–98 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncological and Surgical Sciences, Urology Clinic, University of Padua, Monoblocco Ospedaliero–IV Floor, Via Giustiniani 2, Padua, 35128, Italy

    Vincenzo Ficarra & Giacomo Novara

Authors
  1. Vincenzo Ficarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giacomo Novara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincenzo Ficarra.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ficarra, V., Novara, G. Neoadjuvant targeted therapies in renal cell carcinoma. Nat Rev Urol 7, 63–64 (2010). https://doi.org/10.1038/nrurol.2010.2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2010.2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer